ENTO vs EPWK Comparison

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

EPWK Holdings Ltd create an innovative and efficient crowdsourcing platform to connect businesses with great talents. It operates online marketplace to enable businesses (buyers) and service providers (sellers) to find each other. The platform users consist of buyers who seek talents for their jobs and sellers who offer different talents and skills. The company derives revenue mainly comes from providing various value-added services for users on both supply and demand sides.